ALTEOGEN Inc - Asset Resilience Ratio
ALTEOGEN Inc (196170) has an Asset Resilience Ratio of 49.53% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of ALTEOGEN Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how ALTEOGEN Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of ALTEOGEN Inc.
Liquid Assets Composition Over Time
This chart breaks down ALTEOGEN Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ALTEOGEN Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩366.47 Billion | 49.53% |
| Total Liquid Assets | ₩366.47 Billion | 49.53% |
Asset Resilience Insights
- Very High Liquidity: ALTEOGEN Inc maintains exceptional liquid asset reserves at 49.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ALTEOGEN Inc Industry Peers by Asset Resilience Ratio
Compare ALTEOGEN Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for ALTEOGEN Inc (2014–2025)
The table below shows the annual Asset Resilience Ratio data for ALTEOGEN Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 52.04% | ₩363.64 Billion ≈ $246.43 Million |
₩698.74 Billion ≈ $473.53 Million |
+6.75pp |
| 2024-12-31 | 45.29% | ₩185.25 Billion ≈ $125.54 Million |
₩409.01 Billion ≈ $277.18 Million |
+2.10pp |
| 2023-12-31 | 43.19% | ₩110.61 Billion ≈ $74.96 Million |
₩256.10 Billion ≈ $173.56 Million |
-8.76pp |
| 2022-12-31 | 51.95% | ₩127.54 Billion ≈ $86.43 Million |
₩245.49 Billion ≈ $166.37 Million |
-25.64pp |
| 2021-12-31 | 77.59% | ₩202.00 Billion ≈ $136.90 Million |
₩260.34 Billion ≈ $176.43 Million |
-6.36pp |
| 2020-12-31 | 83.95% | ₩133.66 Billion ≈ $90.58 Million |
₩159.21 Billion ≈ $107.89 Million |
+11.87pp |
| 2019-12-31 | 72.08% | ₩61.98 Billion ≈ $42.00 Million |
₩85.98 Billion ≈ $58.27 Million |
-0.09pp |
| 2018-12-31 | 72.17% | ₩51.52 Billion ≈ $34.91 Million |
₩71.38 Billion ≈ $48.37 Million |
-3.23pp |
| 2017-12-31 | 75.40% | ₩32.43 Billion ≈ $21.98 Million |
₩43.01 Billion ≈ $29.15 Million |
-2.43pp |
| 2016-12-31 | 77.82% | ₩37.32 Billion ≈ $25.29 Million |
₩47.95 Billion ≈ $32.49 Million |
+29.84pp |
| 2015-12-31 | 47.99% | ₩18.90 Billion ≈ $12.81 Million |
₩39.39 Billion ≈ $26.69 Million |
+9.39pp |
| 2014-12-31 | 38.60% | ₩14.65 Billion ≈ $9.93 Million |
₩37.96 Billion ≈ $25.72 Million |
-- |
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more